LBF20203PG01: Difference between revisions
No edit summary |
No edit summary |
||
| (17 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
| Line 4: | Line 6: | ||
|LipidBank=XPR1706 | |LipidBank=XPR1706 | ||
|LipidMaps=LMFA03010143 | |LipidMaps=LMFA03010143 | ||
|SysName=9- | |SysName=9-Oxo- (11alpha,15S) -dihydroxy-prosta- (trans-13,cis-17) -dien-1-oic acid | ||
|Common Name=&& | |Common Name=&&delta^{17}-Prostaglandin E_1&&9-Oxo- (11alpha,15S) -dihydroxy-prosta- (13E,17Z) -dien-1-oic acid | ||
|Source= Delta ^{17}-PGE1 is produced by the cyclooxigenase metabolism of omega -3 arachidonic acid. | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
|Biological Activity= Delta ^{17}-PGE1 is about half as potent as PGE1 as an inhibitor of ADP-induced aggregation of rabbbit PRP.[[Reference:Kobzar_G:Mardla_V:Jarving_I:Lohmus_M:Vahemets_A:Samel_N:Lille_U:,Comp. Biochem. Physiol. C,1993,106,489|{{RelationTable/GetFirstAuthor|Reference:Kobzar_G:Mardla_V:Jarving_I:Lohmus_M:Vahemets_A:Samel_N:Lille_U:,Comp. Biochem. Physiol. C,1993,106,489}}]] In humanPRP, Delta ^{17}-PGE1 is a more potent antiplatelet agonist than PGE1. | |||
}} | }} | ||
{{Lipid/Footer}} | |||
Latest revision as of 17:20, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1706 |
| LipidMaps | LMFA03010143 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20203PG01 |
| δ17-Prostaglandin E1 | |
|---|---|
| |
| Structural Information | |
| 9-Oxo- (11α,15S) -dihydroxy-prosta- (trans-13,cis-17) -dien-1-oic acid | |
| |
| Formula | C20H32O5 |
| Exact Mass | 352.224974134 |
| Average Mass | 352.46508 |
| SMILES | C(=CC[C@@H](O)C=C[C@H]([C@H]1CCCCCCC(O)=O)[C@@H](CC1=O)O)CC |
| Physicochemical Information | |
| Delta ^{17}-PGE1 is produced by the cyclooxigenase metabolism of omega -3 arachidonic acid. | |
| Delta ^{17}-PGE1 is about half as potent as PGE1 as an inhibitor of ADP-induced aggregation of rabbbit PRP. Kobzar_G et al. In humanPRP, Delta ^{17}-PGE1 is a more potent antiplatelet agonist than PGE1. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
